Clinical Research Directory

Browse clinical research sites, groups, and studies.

Sites Groups Studies

Back to Studies

NOT YET RECRUITING

NCT07896486

Evaluating a Brightening Serum for Post-Inflammatory Hyperpigmentation

Sponsor: Weill Medical College of Cornell University

View on ClinicalTrials.gov

Summary

This study is designed to evaluate the effectiveness and safety of Vinoperfect, a skin-brightening serum, for treating post-inflammatory hyperpigmentation (PIH), or dark spots that can develop after acne, in participants with Fitzpatrick Skin Types IV-VI (medium to deep skin tones). The study will assess Vinoperfect as part of a comprehensive skincare routine that includes cleansing, treatment, moisturization, and protection from sunlight.

Official title: A Single-Center, Open-Label Study to Assess the Efficacy and Tolerability of a Brightening Serum in Skin of Color Patients With Post Inflammatory Hyperpigmentation

Key Details

Gender

All

Age Range

18 Years - Any

Study Type

INTERVENTIONAL

Enrollment

Start Date

2026-09

Completion Date

2027-01-15

Last Updated

2026-10-30

Healthy Volunteers

Conditions

Post-inflammatory Hyperpigmentation Post-acne Hyperpigmentation

Interventions

OTHER

Vinoperfect brightening serum

Participants will undergo a standardized twice-daily skincare regimen for 12 weeks. In the morning, participants will cleanse their face, apply the Vinoperfect Brightening Serum, apply moisturizer, and then apply SPF 50+ sunscreen. In the evening, participants will cleanse their face, apply the Vinoperfect Brightening Serum, and apply moisturizer.

Inclusion Criteria: 1. Male or female participants aged ≥18 years. 2. Participants with Fitzpatrick Skin Types IV, V, or VI. 3. Participants of any ethnicity. 4. Presenting with moderate to severe post-inflammatory hyperpigmentation, as determined by a PAHPI score of 8 or higher. 5. Presenting with history or presence of mild acne, as indicated by a Global Acne Severity Score of 2 or lower (GEA ≤ 2). 6. Capable of understanding and communicating in English, and willing to provide written informed consent to participate in the study. 7. Willing to comply with study requirements, including attending all scheduled in-person follow-up visits as outlined in the protocol. 8. Willing to undergo facial photography. 9. Willing to undergo facial examination for clinical evaluation. 10. In good general health, free of any other dermatologic conditions that may interfere with the assessment of the treated area. 11. Willing to refrain from using any other facial skincare products during the study period. 12. Willing to avoid excessive sun exposure and tanning beds during the study period. 13. Willing to refrain from undergoing chemical peels, laser rejuvenation, or hair removal treatments during the study period. 14. For females of childbearing potential: willing to use at least one reliable form of contraception, defined as stable use of oral or systemic contraceptives for at least 6 months prior to Day 1 of the study and throughout the study duration. Exclusion Criteria: 1. Participants with Fitzpatrick Skin Types I, II, or III. 2. Pregnant or breastfeeding participants. 3. Individuals presenting with moderate to very severe acne, as indicated by a Global Acne Severity Score of 3 or higher (GEA \> 3). 4. Participants with known allergies or sensitivities to any active or inactive ingredients in the study products. 5. Participants with dermatologic conditions that may interfere with the evaluation of the treatment area. 6. Individuals with regular sun exposure or frequent use of tanning salons. 7. Participants currently enrolled in another clinical study. 8. Participants who have used the following treatments or procedures within a specific washout periods (to be discussed with the study investigators).

Locations (1)

Weill Cornell Medicine Dermatology

New York, New York, United States